文献速递慢性肾脏病

透析前CKD中体重指数和代谢参数变异性的预后意义:全国性观察性队列研究

The Prognostic Significance of Body Mass Index and Metabolic Parameter Variabilities in Predialysis CKD: A Nationwide Observational Cohort Study.
PubMed 文献 · J Am Soc Nephrol · 2021-08-12

本研究基于韩国全国健康筛查数据库,纳入84,636例透析前CKD患者,评估体重指数(BMI)或代谢参数变异性与预后的关系。结果显示,较高的BMI变异性与全因死亡、肾脏替代治疗(KRT)、心肌梗死和卒中风险显著增加相关,某些代谢综合征组分(如空腹血糖)的高变异性也与不良预后相关。

要点

  • BMI变异性最高四分位组与最低组相比,全因死亡风险显著增加(HR 1.66)。
  • BMI高变异性还增加KRT、心肌梗死和卒中风险。
  • 代谢综合征组分高变异性数量越多,预后越差。

核心结论

  • 较高的BMI和某些代谢综合征组分变异性与透析前CKD患者更差预后显著相关。

研究设计与样本

  • 回顾性观察性研究,基于韩国全国健康筛查数据库,纳入84,636例透析前CKD患者(eGFR<60 ml/min per 1.73 m2或尿白蛋白≥1),暴露为基线前BMI或代谢参数变异性(以独立于均值的变异计算并四分位分组),采用Cox回归分析全因死亡、心肌梗死、卒中和KRT风险。

主要发现

  • BMI变异性最高四分位组(Q4)与最低组(Q1)相比,全因死亡风险显著增加(HR 1.66;95%CI 1.53-1.81;P for trend <0.001)。
  • BMI变异性Q4 vs Q1的KRT风险HR 1.20(95%CI 1.09-1.33;P<0.001)。
  • BMI变异性Q4 vs Q1的心肌梗死风险HR 1.19(95%CI 1.05-1.36;P=0.003)。
  • BMI变异性Q4 vs Q1的卒中风险HR 1.19(95%CI 1.07-1.33;P=0.01)。
  • 某些代谢综合征组分(如空腹血糖)的变异性也与透析前CKD患者预后显著相关,且高变异性组分数量越多预后越差。

关键数值与推荐

  • BMI变异性以独立于均值的变异计算并四分位分组,Q4为最高四分位。
  • 代谢综合征组分高变异性数量越多,预后越差。

临床怎么用

  • 在透析前CKD患者管理中,应关注BMI和代谢参数(如空腹血糖)的长期变异性,而不仅看单次测量值。
  • 高变异性可能提示需要更密切监测和干预以改善预后。

局限性

  • 回顾性观察性研究,可能存在残余混杂。
  • 变异性计算基于健康筛查数据,筛查间隔可能影响结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The association between variabilities in body mass index (BMI) or metabolic parameters and prognosis of patients with CKD has rarely been studied. METHODS: In this retrospective observational study on the basis of South Korea's national health screening database, we identified individuals who received ≥3 health screenings, including those with persistent predialysis CKD (eGFR <60 ml/min per 1.73 m2 or dipstick albuminuria ≥1). The study exposure was variability in BMI or metabolic parameters until baseline assessment, calculated as the variation independent of the mean and stratified into quartiles (with Q4 the highest quartile and Q1 the lowest). We used Cox regression adjusted for various clinical characteristics to analyze risks of all-cause mortality and incident myocardial infarction, stroke, and KRT. RESULTS: The study included 84,636 patients with predialysis CKD. Comparing Q4 versus Q1, higher BMI variability was significantly associated with higher risks of all-cause mortality (hazard ratio [HR], 1.66; 95% confidence interval [95% CI], 1.53 to 1.81), P [for trend] <0.001), KRT (HR, 1.20; 95% CI, 1.09 to 1.33; P<0.001), myocardial infarction (HR, 1.19; 95% CI, 1.05 to 1.36, P=0.003), and stroke (HR, 1.19; 95% CI, 1.07 to 1.33, P=0.01). The results were similar in the subgroups divided according to positive or negative trends in BMI during the exposure assessment period. Variabilities in certain metabolic syndrome components (e.g., fasting blood glucose) also were significantly associated with prognosis of patients with predialysis CKD. Those with a higher number of metabolic syndrome components with high variability had a worse prognosis. CONCLUSIONS: Higher variabilities in BMI and certain metabolic syndrome components are significantly associated with a worse prognosis in patients with predialysis CKD.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Park S, Cho S, Lee S, et al. The Prognostic Significance of Body Mass Index and Metabolic Parameter Variabilities in Predialysis CKD: A Nationwide Observational Cohort Study. J Am Soc Nephrol. 2021. PMID: 34385363. doi:10.1681/ASN.2020121694

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。